Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918197 | 0.88 | TSHR (0.55) | TSHRALDH1A1TDP1 | |
| SCHEMBL23713956 | 0.79 | TSHR (0.46) | TSHRALDH1A1TDP1 | |
| SCHEMBL26507941 | 0.77 | TSHR (0.44) | TSHRALDH1A1TDP1 | |
| SCHEMBL25486253 | 0.77 | TSHR (0.44) | TSHRALDH1A1TDP1 | |
| SCHEMBL14791095 | 0.76 | TSHR (0.54) | TSHRALDH1A1TDP1 | |
| SCHEMBL26498131 | 0.71 | TSHR (0.42) | TSHRALDH1A1TDP1 | |
| SCHEMBL9918268 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL25891679 | 0.70 | — | — | |
| SCHEMBL9918270 | 0.69 | TSHR (0.36) | TSHR | |
| SCHEMBL6583234 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TSHR 2900/4885ALDH1A1 1654/4885TDP1 2655/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TSHR 2606/4885ALDH1A1 1507/4885TDP1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.